Clinical Trial Update: Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the safety and preliminary efficacy results from a Phase 1/2 study of INC280 (capmatinib) and buparlisib (BKM120) in patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Buparlisib (BKM-120) (buparlisib)
• Capmatinib (INC280) (capmatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-05-24